Navigation Links
Immune Targeting Systems and WCCT Global Announce a New Influenza A H1N1 Virus to Support the Experimental Human Viral Challenge Model
Date:8/18/2014

ion and other standard containment provisions to accommodate this valuable research model and ensure the safety and comfort of the volunteers and staff. 

Benjamin Chen, PhD, CEO of Immune Targeting Systems said, "We are very excited that WCCT Global has taken over the ownership of this important clinical research tool and are confident that they will use the virus to help support the development of new vaccines and antiviral drugs".  Kenneth Kim, MD, CEO of WCCT Global said, " The capability to carry out the experimental influenza challenge model in conjunction with our deep-seated expertise in anti-viral drug development will surely be of great interest to our sponsors. This new capability combined with our Full Service Global capabilities, specialized influenza project teams, and deep scientific knowledge allows WCCTG to manage vaccine and antiviral development programs from First in Man through NDA submission."

More about Immune Targeting Systems

Immune targeting Systems, Ltd develops T-cell vaccines to highly mutated viruses and to cancers. The company's lead product  Flunisyn™ vaccine has been shown in three clinical studies to stimulate the production of T-cells that recognise and destroy influenza-infected cells. Flunisyn™  is a pan-influenza A vaccine applicable to multiple influenza strains without the need to be re-manufactured for each influenza season or pandemic outbreak.  The Company is also advancing the development of two other product candidates: a therapeutic Hepatitis B vaccine for chronic hepatitis B and a cancer vaccine for solid tumours. ITS is supported by Novartis Venture fund, Truffle Capital, HealthCap, Esperante Ventures and SME wholesale Finance.

More about WCCT Global

WCCT Global is a multi-site, full service pharmaceutical contract res
'/>"/>

SOURCE WCCT Global
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Immune Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Update on Bertilimumab Commencement of Phase II Clinical Trials
2. Novimmune Reports Successful Completion of Phase I trial for NI-0101
3. Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin
4. UMD Researcher Helps Arm the Immune System to Fight Cancer
5. Immunotherapies Will Continue to Dominate the Malignant Melanoma Drug Market with Sales of Immune Checkpoint Inhibitors Accounting for Majority of Sales in this Drug Class in 2022
6. BHI Elects MedImmunes Reg Seeto, M.D. to Board of Directors
7. Global Autoimmune Disease Diagnostics Market
8. NW Bio Responds To Shareholder Inquiries Following Immune Therapy Sectors Recent Market Decline
9. High Cost of Biologics and Novel Oral Agents to Treat Immune Diseases Limits Patient Access
10. Immune Pharmaceuticals Reports Third Quarter 2013 Financial Results
11. Unilife Announces Supply Agreement with MedImmune for Wearable Injectable Drug Delivery Devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... and SOUTHAMPTON , ... pharmaceutical company Pharmaxis Ltd (ASX: PXS) and UK biotechnology company ... a research collaboration to develop a selective inhibitor to the ... lung disease idiopathic pulmonary fibrosis (IPF). IPF ... Current products are expected to produce global revenues in excess ...
(Date:8/4/2015)... On August 3, 2015, a press conference on anti-virus and ... ceremony of a million masks by Wuhan Longfeixiang Technology Products ... . Wuhan Longfeixiang Technology Products ... Longfeixiang Industrial Group, which has successfully developed the globally ... mask, filling the global gap for masks of this ...
(Date:8/4/2015)... Aug. 4, 2015 Young Innovations ("Young"), ... equipment, today announced the acquisition of the professional ... Inc. ("MPL PDCMD"). MPL PDCMD manufactures fluoride varnish, ... and restorative dental procedures. "This ... business in attractive, high-growth segments," said Dave ...
Breaking Medicine Technology:Pharmaxis and Synairgen Announce Research Collaboration to Develop LOXL2 Inhibitor For Pulmonary Fibrosis 2Pharmaxis and Synairgen Announce Research Collaboration to Develop LOXL2 Inhibitor For Pulmonary Fibrosis 3Young Innovations Announces Acquisition of Medical Products Laboratories' Professional Dental Contract Manufacturing Division 2
... 11, 2011 TriMed, Inc., a developer and manufacturer of ... has reached an agreement to license its "pin plate" device ... 5,931,839 and ends a four-year patent infringement suit. The agreement ... Radial Pin Plate and Ulnar Pin Plate in 1995 for ...
... and Nova Scotia, CANADA, Jan. 11, 2011 ... "Emerging Professional Award" for his work in computer-aided ... the 8th annual Discovery Awards dinner sponsored by ... TREVENTIS with a proprietary drug discovery system called ...
Cached Medicine Technology:TriMed, Inc. Announces Licensing Agreement with Stryker 2TREVENTIS Corporation Founder Wins Prestigious Discovery Award 2
(Date:8/4/2015)... , ... August 04, 2015 , ... ... on sexual and reproductive health and rights in Indonesia for a select group ... a number of sites in Indonesia and attend the International Conference on Family ...
(Date:8/4/2015)... ... 04, 2015 , ... Wimbledon Health Partners , the ... testing, announced their collegiate division, Wimbledon U , continues to not just ... at a time. , “Wimbledon U welcomes the eight new Colleges ...
(Date:8/4/2015)... ... August 04, 2015 , ... An article published July ... be a viable method for encouraging people to lose weight. Specifically the study compared ... their weight loss success, adding a financial incentive to the overall incentive of increased ...
(Date:8/4/2015)... ... ... Bayco Products, Inc. announces a new industrial-grade LED Dual-LightTM headlamp in a new, ... a flip-up face shield. The sleek contours of the new Nightstick NSP-4614B Low-Profile ... headlamp when raising or lowering their face shield or visor. The 4614 will be ...
(Date:8/4/2015)... Santa Barbara, CA (PRWEB) , ... August 04, ... ... if you are suffering from underarm sweat. Evolutions Medical & Day Spa in ... called miraDry, the only non-invasive, FDA cleared treatment that permanently eliminates sweat and ...
Breaking Medicine News(10 mins):Health News:UN Foundation Announces Press Fellowship to Indonesia with Focus on Women’s Health and Rights 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 3Health News:Article on Incentivizing Weight Loss Mirrors Similar Motivations Surrounding Weight Loss Surgery, Says Dr. Feiz & Associates 2Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 2Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 3Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 3
... Reddy's Laboratories, one of India's largest manufacturers of generic medicines,// ... bid for a major European company - the generics arm ... a look at it and then decide," G.V. Prasad, Dr ... He added that any bid from Dr Reddy's would be ...
... the important role a certain protein plays in the mating ... cancer drugs with fewer side effects. // ,A research ... have revealed in the journal Nature how they used their ... research has solved a long-standing mystery of how a specific ...
... at Buffalo and the University of Utah are beginning a clinical ... becoming pregnant and of maintaining a pregnancy to term. // ... grant from the National Institute of Child Health and Development. ... a pregnancy in the past year. ,"In women ...
... absence of a key signaling protein in the brain ... life, scientists say. //According to findings published today in ... the chemical messenger serotonin just after birth exhibit abnormal ... some time that mice genetically engineered to lack the ...
... in patients over age 65, according to a new ... ,ADT is one of the most common treatments for ... on data from CaPSURE, a national registry of men ... confirmed in clinical trials, the study authors state that ...
... A Nigerian medical doctor who contracted Lassa fever in ... Pretoria, //the Gauteng Department of Health said on Wednesday. ... is receiving treatment in the hospital's special isolation ward," ... the department's Chief of Operations Dr Abdul Rahman, the ...
Cached Medicine News:Health News:Dr Reddy's Eyeing for Generics Arm of Merck 2Health News:Biochemical Chip Solves Cell-mating Puzzle 2Health News:Biochemical Chip Solves Cell-mating Puzzle 3Health News:Study to Look at Aspirin as Aid to Conception, Healthy Pregnancy 2Health News:Mouse Study Suggests Anxiety Disorders Take Root in Infancy 2Health News:Benefits of ADT Against Risk of Heart Ailments 2Health News:South Africa: Nigerian Man Treated for Lassa Fever 2
A new generation of enhancing color contact lens designed specifically for light eyes....
Expressions Accents contact lenses let you enhance your eyes natural color while enjoying incredible comfort and outstanding vision quality....
... The Vasculight VS system improves the appearance ... freckles), most benign brown pigments, telangiectasias, and ... Intense Pulsed Light (IPLTM) treats pigmentary sun ... unique, combined approach of IPL and the ...
... Crazy Lenses are fun, affordable lenses ... designs. Crazy lenses are available in ... vision correction, and in "Plano" for ... using our patented Ultrasync technology. Incredibly ...
Medicine Products: